Literature DB >> 34601504

Histopathologic, immunophenotypic, and mutational landscape of follicular lymphomas with plasmacytic differentiation.

Sarah E Gibson1,2,3, Yen-Chun Liu4,5,6, Svetlana A Yatsenko4,5, Nicholas J Barasch5,7, Steven H Swerdlow4,5.   

Abstract

Follicular lymphomas with plasmacytic differentiation (FL-PCD) include two major subtypes: one with predominantly interfollicular PCD that usually harbors a BCL2 rearrangement (BCL2-R), and a second that has predominantly intrafollicular PCD and the frequent absence of a BCL2-R. It is proposed that these latter cases share some features with marginal zone lymphomas (MZL). To further explore this hypothesis in an expanded cohort of FL-PCD, a clinicopathologic investigation of 25 such cases was undertaken including an analysis of their mutational landscape. The 10 interfollicular FL-PCDs exhibited typical intrafollicular centrocytes/centroblasts (90%), CD10 expression (90%), full PCD including expression of CD138 by the plasma cells (PC) (100%), and PCs with class-switched immunoglobulin heavy chains (70%). These cases were BCL2-R positive (100%), BCL6-R positive in 30%, lacked extra BCL2 copies, and only 22% had extra copies of BCL6. Similar to classic FLs, 80% of interfollicular FL-PCDs harbored mutations in epigenetic regulators KMT2D (70%), CREBBP (40%), and/or EZH2 (30%). In contrast, only 45% of 11 intrafollicular FL-PCDs demonstrated typical intrafollicular centrocytes/centroblasts, 55% were CD10(-), 80% contained IgM+ PCs, and only 27% harbored BCL2-Rs. BCL6-Rs were identified in 27% of intrafollicular FL-PCD, while 60% showed extra copies of BCL2 and 50% extra copies of BCL6, consistent with complete or partial trisomies of chromosomes 18 and 3, respectively. Only 54% of intrafollicular FL-PCDs showed mutations in epigenetic regulators. Both subtypes showed mutational differences compared to classic FL, but only the interfollicular subtype showed differences from what is reported for nodal MZL. Four additional cases showed mixed intra- and interfollicular PCD. These results suggest that FL-PCD has some distinctive features and supports the existence of two major subtypes. The interfollicular PCD subtype shares many features with classic FL. The intrafollicular FL-PCDs are more heterogeneous, have differences from classic FL, and have a greater morphologic, immunophenotypic, and genetic overlap with MZL.
© 2021. The Author(s), under exclusive licence to United States & Canadian Academy of Pathology.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34601504     DOI: 10.1038/s41379-021-00938-z

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  49 in total

1.  Clinical significance of follicular lymphoma with monocytoid B cells. Non-Hodgkin's Lymphoma Classification Project.

Authors:  B N Nathwani; J R Anderson; J O Armitage; F Cavalli; J Diebold; M R Drachenberg; N L Harris; K A MacLennan; H K Müller-Hermelink; F A Ullrich; D D Weisenburger
Journal:  Hum Pathol       Date:  1999-03       Impact factor: 3.466

2.  Follicular lymphoma with marginal zone differentiation: microdissection demonstrates the t(14;18) in both the follicular and marginal zone components.

Authors:  S Yegappan; B Schnitzer; E D Hsi
Journal:  Mod Pathol       Date:  2001-03       Impact factor: 7.842

Review 3.  Molecular pathogenesis of germinal center-derived B cell lymphomas.

Authors:  Laura Pasqualucci
Journal:  Immunol Rev       Date:  2019-03       Impact factor: 12.988

4.  Follicular lymphoma with marginal zone differentiation: cytogenetic findings in support of a high-risk variant of follicular lymphoma.

Authors:  J R Goodlad; P J Batstone; D Hamilton; K Hollowood
Journal:  Histopathology       Date:  2003-03       Impact factor: 5.087

5.  A marginal zone phenotype in follicular lymphoma with t(14;18) is associated with secondary cytogenetic aberrations typical of marginal zone lymphoma.

Authors:  E E Torlakovic; H V Aamot; S Heim
Journal:  J Pathol       Date:  2006-06       Impact factor: 7.996

6.  Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease.

Authors:  Dominik Nann; Joan Enric Ramis-Zaldivar; Inga Müller; Blanca Gonzalez-Farre; Janine Schmidt; Caoimhe Egan; Julia Salmeron-Villalobos; Guillem Clot; Sven Mattern; Franziska Otto; Barbara Mankel; Dolors Colomer; Olga Balagué; Vanessa Szablewski; Carmen Lome-Maldonado; Lorenzo Leoncini; Stefan Dojcinov; Andreas Chott; Christiane Copie-Bergman; Irina Bonzheim; Falko Fend; Elaine S Jaffe; Elias Campo; Itziar Salaverria; Leticia Quintanilla-Martinez
Journal:  Blood Adv       Date:  2020-11-24

7.  Follicular lymphomas with plasmacytic differentiation include two subtypes.

Authors:  Joel F Gradowski; Elaine S Jaffe; Roger A Warnke; Stefania Pittaluga; Urvashi Surti; Leena A Gole; Steven H Swerdlow
Journal:  Mod Pathol       Date:  2009-10-16       Impact factor: 7.842

8.  Fluorescence in situ hybridization identifies new chromosomal changes involving 3q27 in non-Hodgkin's lymphomas with BCL6/LAZ3 rearrangement.

Authors:  I Wlodarska; C Mecucci; M Stul; L Michaux; S Pittaluga; J M Hernandez; J J Cassiman; C De Wolf-Peeters; H Van den Berghe
Journal:  Genes Chromosomes Cancer       Date:  1995-09       Impact factor: 5.006

9.  Plasmacytic differentiation in follicular center cell (FCC) lymphomas.

Authors:  T A Keith; J B Cousar; A D Glick; L B Vogler; R D Collins
Journal:  Am J Clin Pathol       Date:  1985-09       Impact factor: 2.493

10.  Human germinal center transcriptional programs are de-synchronized in B cell lymphoma.

Authors:  Pierre Milpied; Iñaki Cervera-Marzal; Marie-Laure Mollichella; Bruno Tesson; Gabriel Brisou; Alexandra Traverse-Glehen; Gilles Salles; Lionel Spinelli; Bertrand Nadel
Journal:  Nat Immunol       Date:  2018-08-13       Impact factor: 25.606

View more
  1 in total

1.  CD11c+ B Cells Participate in the Pathogenesis of Graves' Disease by Secreting Thyroid Autoantibodies and Cytokines.

Authors:  Yedi Cao; Xue Zhao; Ran You; Yang Zhang; Chenxue Qu; Youyuan Huang; Yang Yu; Yan Gong; Tiechuan Cong; Enmin Zhao; Lanbo Zhang; Ying Gao; Junqing Zhang
Journal:  Front Immunol       Date:  2022-03-21       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.